This story originally ran on April 12.
Kinaxo Biotechnologies said this week it has been granted a European patent covering its proteomics technology.
Entitled "Proteome-wide quantification of small molecule binding to cellular target proteins," the patent encompasses the company's Cellular Target Profiling, KinAffinity, and Epigenetics Target Profiling services.
Kinaxo's KinAffinity and Epigenetics Target products combine chemical proteomics methods with quantitative mass spectrometry to generate target selectivity data for kinase inhibitors and epigenetic drugs, respectively. The Cellular Target Profiling service offers analysis of potential off-target interactions for compounds across the proteome of a given cell line or tissue sample.
Such data "significantly supports decision-making at various stages of the drug development process," said Henrik Daub, Kinaxo's chief technology officer, in a statement.
The company, which drug developer Evotec agreed in February to purchase for up to €16 million ($22 million) in cash and stock (GWDN 02/09/2011), has inked a number of deals in recent months for the use of its technology, with customers including pharmaceutical firms like Takeda (PM 03/18/2011), AstraZeneca (PM 01/07/2011), and Bristol-Myer Squibb (GWDN 10/11/2010).
Patent applications for the technology are pending in the United States and Japan, Kinaxo said.